Transaction DateRecipientSharesTypePriceValue
30th September 2020Vipin K Garg2,015Payment by withholding$13.20$26,598.00
24th September 2020David Drutz16,850Exercise of derivative$0.00
24th September 2020Mitchel Sayare25,275Exercise of derivative$0.00
24th September 2020Wayne Pisano16,850Exercise of derivative$0.00
24th September 2020Philip Hodges16,850Exercise of derivative$0.00
24th September 2020John Gill16,850Exercise of derivative$0.00
24th September 2020Klaus Schafer16,850Exercise of derivative$0.00
30th August 2020Vipin K Garg2,015Payment by withholding$17.62$35,504.30
18th August 2020Healthcare Capital Partners Iii, L.P. Venrock101,000Open or private purchase$2.62$264,620.00
17th August 2020Healthcare Capital Partners Iii, L.P. Venrock250,000Open or private purchase$2.57$642,500.00
Altimmune
Altimmune logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.


Altimmune, Inc. is a clinical stage immunotherapeutic biotechnology company. Its portfolio includes RespirVec and Densigen that targets to stimulate the elements of the human immune system.


Ticker: ALT
Sector: Commercial Services
Industry: Miscellaneous Commercial Services
SEC Central Index Key (CIK): 1326190
Employees: 25
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals